K

Kadimastem Ltd
OTC:KMSTF

Watchlist Manager
Kadimastem Ltd
OTC:KMSTF
Watchlist
Price: 2.23 USD 6.7% Market Closed
Market Cap: 2m USD

Kadimastem Ltd
Investor Relations

Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Ronen Twito CPA
Executive Chairman & President
No Bio Available
Mr. Uri Ben-Or
Chief Financial Officer
No Bio Available
Prof. Michel Revel M.D., Ph.D.
Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director
No Bio Available
Mr. Yossi Ben-Yossef
Honorary President & Strategic Consultant
No Bio Available
Mr. Olivier Samuel
VP of European Business Development & Director
No Bio Available

Contacts

Address
Ness Ziona
Pinchas Sapir 7, Weizmann Science Park
Contacts
+972737971600.0
kadimastem.com